Almost a year after its $57 million Series A private equity financing, Aspreva Pharmaceuticals Inc. priced its initial public offering of 7.2 million shares at $11 per share (C$13.68), raising $79.2 million for the Victoria, British Columbia-based firm. (BioWorld Today) Read More
